Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

Core Viewpoint - Yirui Technology's stock has shown a positive trend with a year-to-date increase of 8.66% and a recent uptick of 2.02% on January 6, 2025, indicating strong market interest and performance in the medical device sector [1]. Group 1: Stock Performance - As of January 6, 2025, Yirui Technology's stock price reached 109.87 yuan per share, with a trading volume of 2.24 billion yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 23.232 billion yuan [1]. - The stock has experienced a 6.67% increase over the last five trading days and an 8.41% increase over the last 20 trading days, while it has seen a decline of 5.01% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yirui Technology reported a revenue of 1.549 billion yuan, reflecting a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million yuan, which is a 20.61% increase compared to the previous year [2]. - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Yirui Technology increased to 8,011, marking a 14.61% rise, while the average number of circulating shares per person decreased by 12.74% to 24,992 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant holding 3.802 million shares, while Huabao Zhongzheng Medical ETF has exited the list [3]. Group 4: Business Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and service of digital X-ray detectors, with the main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with various concepts including medical devices, mid-cap stocks, margin financing, security, and share buybacks [1].

Core Viewpoint - As of September 30, the company reported a total of 8,011 ordinary shareholders [1] Company Summary - The company, Yirui Technology, has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [1]

Core Viewpoint - The company plans to invest up to RMB 180 million in a silicon-based OLED microdisplay backplane production project through its wholly-owned subsidiary, aiming to enhance production capacity and meet market demand [1] Group 1: Investment Details - The investment will be executed by Yirui Imaging Technology (Hefei) Co., Ltd. as the implementation entity [1] - The project is expected to add a production capacity of 5,000 units per month for silicon-based OLED microdisplay backplanes [1] - The construction period for the project is estimated to be 12 months, and it is currently still under construction [1]

Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company is expected to maintain high growth due to the expansion of its OLED microdisplay backplane business through a capital increase and introduction of strategic investors [3] - The company reported strong performance in the first three quarters of 2025, with revenue of 1.549 billion yuan, a year-on-year increase of 14.22%, and a net profit of 471 million yuan, up 20.61% [4] - The company is increasing its R&D investment to accelerate product innovation, with key products expected to launch in 2026, which will enhance its competitive edge [5] - Revenue projections for 2025-2027 are 2.32 billion yuan, 2.90 billion yuan, and 3.73 billion yuan respectively, with net profits of 629 million yuan, 838 million yuan, and 1.028 billion yuan [6] Company Overview - The latest closing price of the company's stock is 101.11 yuan, with a total market capitalization of 21.4 billion yuan [2] - The company has a total share capital of 211 million shares, with 200 million shares in circulation [2] - The company has a debt-to-asset ratio of 48.8% and a price-to-earnings ratio of 31.02 [2]

Core Viewpoint - The company is progressing with its "X-ray vacuum device and comprehensive solution construction project" as planned, with ongoing product development and customer integration [2] Group 1: Product Development - The company has completed the research and development of several types of X-ray tubes, including micro-focus tubes, transmission target tubes, dental intraoral tubes, DR tubes, C-arm tubes, and some CT tubes [2] - Micro-focus tubes, transmission target tubes, dental intraoral tubes, and CBCT tubes have already entered mass production [2] - The C-arm tube has completed registration and is transitioning to production, while some DR tubes and CT tubes are expected to start registration in the first quarter of 2026 [2] Group 2: Business Outlook - As the company’s tube products gradually complete registration and commercialization, along with the expansion of its comprehensive solution business, it is anticipated that future orders and self-use quantities will gradually increase [2]

Core Viewpoint - The company, Yirui Technology (688301.SH), has announced a share buyback program, indicating confidence in its financial health and future prospects [1] Group 1: Share Buyback Details - As of December 31, 2025, the company has repurchased a total of 938,800 shares, which represents 0.44% of its total share capital [1] - The highest price paid for the repurchased shares was 104.77 RMB per share, while the lowest price was 98.14 RMB per share [1] - The total amount spent on the share buyback was 95.0663 million RMB, excluding transaction fees such as stamp duty and commissions [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-002 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况，现将公司回购股份的进展情况公告如下： 截至 2025 年 12 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 93.88 万股，占公司总股本的 0.44%，回购最高价格 104.77 元/股，回购最低价格 98.14 元/股，使用资金总额为人民币 9,506.63 万元（不含印 花税、交易佣金等交易费用）。 公司本次实际回购的股份数量、回购价格、使用资金总额符合董事会审议通 过的回购报告书及相关法律法规的规定。 | ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-001 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 累计转股情况：截止2025年12月31日，"奕瑞转债"累计有人民币 13,277,000元已转换为奕瑞电子科技集团股份有限公司（以下简称"公司"或"奕瑞 科技"）股票，转股数量为57,702股，占"奕瑞转债"转股前公司已发行股份总额的 0.0567%； 未转股可转债情况：截止2025年12月31日，"奕瑞转债"尚未转股的可转 债金额为1,421,733,000元，占"奕瑞转债"发行总量的99.0748%； 本季度转股情况：自2025年10月1日起至2025年12月31日，"奕瑞转债" 共有人民币2,000元已转换为公司股票，转股数量为16股，占"奕瑞转债"转股前 公司已发行股份总额的0.0000%。 一、可转债 ...

每经AI快讯，奕瑞科技1月5日晚间发布公告称，截至2025年12月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份93.88万股，占公司总股本的0.44%，回购最高价格104.77元/ 股，回购最低价格98.14元/股，使用资金总额为人民币9506.63万元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 （记者 曾健辉） ...